期刊文献+

固体药物多晶型的研究进展 被引量:4

Research Progress on Polymorphs of Solid Medicines
下载PDF
导出
摘要 药物多晶型的研发一直是生物制药领域的研究热点,药物的不同晶态会对药品溶解度、溶出速率、生物利用率等各方面产生重要影响。它也是药品生产质量安全控制中一项关键的环节。它为药物研究提供了一个全新的发展思路。通过梳理、分析和总结近20年来国内外关于药物多晶型的相关文献,介绍了药物多晶型的研究意义、制备方法及其对临床应用的影响。 The research and development of drug polymorphs has always been a research hotspot in the field of biopharmaceuticals.The different crystal states of drugs will have an important impact on drug solubility,dissolution rate,bioavailability and other aspects;it is also one of the quality and safety control of drug production It provides a brand-new development idea for drug research.By combing,analyzing and summarizing the relevant literatures on drug polymorphs at home and abroad in the past 20 years,this article introduces the research significance,preparation methods and their impact on clinical applications of drug polymorphs.
作者 周锋 潘建辉 孙丹玲 邓月义 Zhou Feng;Pan Jianhui;Sun Danling;Deng Yueyi(Pharmacy School of Guilin Medical University,Guilin 541004,China)
出处 《云南化工》 CAS 2021年第12期1-3,共3页 Yunnan Chemical Technology
基金 广西壮族自治区自然科学基金项目(2020GXNSFAA159019)资助。
关键词 药物多晶型 药物质量 药品研发 drug polymorphism drug quality drug development
  • 相关文献

参考文献3

二级参考文献39

  • 1Rolf H. Polymorphism in the Pharmaceutical Industry [M]. Weinheim: WlLEY-VCH Verlag GmbH & Co. KgaA Press, 2000:259-281.
  • 2Kerc J, Srcic S, Mohar M, et al. Some physicochemical properties of glassy felodipine [J]. Int J Pharm, 1991, 68: 25-33.
  • 3Johari GP, Ram S, Astl G .Characterizing amorphous and microcrystalline solids by calorimetry [J]. J Non-Cryst Solids, 1990, 116: 282-285.
  • 4Mishima O, Calvert LD, Whalley E. An apparently firstorder transition between two amorphous phases of ice induced by pressure [J]. Nature, 1985, 314: 76-78.
  • 5Chokshi R J, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons [J]. Drug Deliv, 2007, 14: 33-45.
  • 6Matsunaga N, Nakamura K, Yamamoto A, et al. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window [J]. Mol Cancer Ther, 2006, 5: 80-88.
  • 7Dharmendra S, William C. Drug polymorphism and dosage form design: a practical perspective [J]. Adv Drug Deliv Rev, 2004, 56: 335-347.
  • 8Albano AA, Phuapradit W, Sandhu HK, et al. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability: US, 6482847[P]. 2002-11-19.
  • 9Shikura T, Ishizawa T, Suemune K, et al. Amorphous substance of tricyclic triazolobenzazepine derivative: US, 7229985 [P]. 2007-06-12.
  • 10Chono S, Takeda E, Seki T, et al. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin [J]. Int J Pharm, 2008, 347: 71-78.

共引文献32

同被引文献34

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部